10x Genomics, Inc., a frontrunner in single cell and spatial biology, has announced a definitive agreement to acquire Scale Biosciences, Inc., which specializes in innovative and scalable single cell analysis. This acquisition aims to enrich 10x's Chromium platform by integrating key inventions and technologies, thus enhancing the accessibility and affordability of single cell analysis for researchers globally.

‍

Founded by a diverse team of scientists and technologists skilled in next-generation sequencing, genomics, and bioinformatics, Scale Biosciences has made significant strides in combinatorial indexing and quantum barcoding, crucial for scalable single cell analysis. The scientific founders, who will transition to advisory roles at 10x, include Professor Garry Nolan from Stanford University and Professors Jay Shendure and Cole Trapnell from the University of Washington.

"At 10x, we're relentlessly innovating to build a world where single cell analysis is routine, accessible, and scalable at levels previously unimaginable," said Serge Saxonov, CEO of 10x Genomics. "This acquisition is a step towards that vision – reflecting our commitment to accelerating adoption of single cell technologies. By integrating Scale's inventions with 10x's global platform and innovation engine, we will broaden the capabilities and reach of existing and future products."

The incorporation of Scale's technologies into 10x will enable a wider reach for researchers, fostering more scientific breakthroughs and reinforcing 10x's mission to promote human health. This acquisition aligns with an ambitious multi-year product roadmap focused on scaling the analysis of both the number of cells and samples while maintaining the high-quality multiomic data researchers expect from 10x.

"These inventions were designed to make single cell analysis dramatically more scalable and accessible," noted Garry Nolan, PhD, co-founder of Scale Biosciences and Professor at Stanford University. "They have already advanced biological discovery, and with 10x's innovation engine, that impact will only accelerate. This integration will help the research community generate the high-quality data needed to drive AI-powered breakthroughs in medicine."

Giovanna Prout, President and CEO of Scale Biosciences, expressed pride in their accomplishments, stating, "We are incredibly proud of what we've built at Scale and its impact advancing biological understanding in single cell analysis. Our integration with 10x will accelerate the adoption of our technology, helping it reach new customers and transformative emerging applications. We look forward to 10x building on our pioneering work and supporting a broader global customer base that will drive the next wave of biological discovery."

10x Genomics will continue to support existing Scale customers with their ongoing experiments, alongside initiatives like the 100 Million Cell Challenge and the Billion Cells Project. Additionally, key products from Scale will remain available on the market.

10x Genomics is committed to advancing human health through its life science technology products that enhance the understanding of biological systems. Their integrated research solutions cater to academic, translational researchers, and biopharmaceutical companies, enabling breakthroughs across various fields, including oncology and immunology.